Reirradiation for Prostate, CNS, and Head and Neck Cancers (PRO 05)
This activity has a total of three separate sections covering re-irradiation/retreatment in the CNS (both Primary CNS tumors and in the Metastatic setting), Head and Neck, and Prostate. Discussion of Volumes, Dose Constraints, and Risk/Benefit. Appropriate dose fractionation schemes and clinical decision making is covered during this case-based activity.
Target Audience
This activity is designed to meet the interests of radiation oncologists.
Learning Objectives
Upon completion of this live activity, participants should be able to do the following:
- Know appropriate fractionation schemes for retreatment in the CNS, Head and Neck and Prostate.
- Understand the risk/benefit ration of re-treatment and be able to communicate this to patients.
Sanjeev Aggarwal, MD, is employed by Cancer Center at Lake Manassas and by University of Virginia. Dr. Aggarwal receives compensation from Evolent Health. Dr. Aggarwal owns stock in Zeto, Inc., AVDL, AXSM, Interra Neuroscience, iPath, and AstraZeneca.
Abhishek A. Solanki, MD, MS, is employed by Stritch School of Medicine, Cardinal Bernardin Cancer Center, Loyola University Chicago and also by Edward Hines Jr. VA Hospital. Dr. Solanki receives research funding from the United States Department of Veterans Affairs. Dr. Solanki serves as an Executive Committee Member with the American College of Radiology’s Council of Regional Radiation Oncology Societies Caucus.
Susan L. McGovern, MD, PhD, is employed by The University of Texas MD Anderson Cancer Center and also by Baylor College of Medicine. Dr. McGovern receives compensation from Chimerix.
James Caudell, MD, PhD, is employed by Moffitt Cancer Center. Dr. Caudell receives research funding from Varian Medical Systems.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 1.25 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.